Go Back to Previous Page »

Toprol Antitrust Litigation -- In re Metoprolol Succinate End-Payor Antitrust Litigation

Court: United States District Court, District of Delaware
Case No.:

Wexler Wallace represents United Association of Plumbers and Pipefitters Local 572 – and is co-chair of the discovery committee – in this antitrust class action brought by third-party payors and consumers against AstraZeneca LP and various related drug companies.  The case alleges that, in violation of federal antitrust laws, as well as state unfair competition laws, AstraZeneca improperly manipulated patent filings and filed baseless patent infringement lawsuits in an effort to prevent generic versions of the drug Toprol-XL from entering the market.  Among other things, this unlawful conduct has caused end payors for Toprol-XL to pay significantly higher costs than they should have.


On March 7, 2013, Judge Mary Pat Thynge granted final approval to a settlement that resulted in Defendant AstraZeneca paying up to $11 million to consumers and third-party payors who purchased the heart medication Toprol XL or its generic, metoprolol succinate.